Obesity is a worldwide health problem at increasing incidence associated with high
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …

PURPOSE: There is a paucity of clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy and …

Background: Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia.
Obesity is an independent risk factor for AF. Anticoagulants have been strongly …

Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

Oral anticoagulation (OAC) is the cornerstone for the prevention of stroke in most patients
with atrial fibrillation (AF). The traditional treatment consists of warfarin, but direct oral …

Although obesity is associated with the development and progression of atrial fibrillation
(AF), an obesity paradox may be present, illustrated by seemingly protective effects of …

BACKGROUND: Atrial fibrillation if left untreated increases the risk of stroke by five fold.
Novel oral anticoagulants (NOAC) are being increasingly used as a convenient alternative …

Background Direct‐acting oral anticoagulants are now the preferred method of
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …

Background and aims The association between body mass index (BMI) and clinical
outcomes of patients with non-valvular atrial fibrillation (NVAF) taking oral anticoagulants …

African Americans (AAs) and obese individuals have increased thrombotic risk. This study
evaluated the effectiveness and safety of rivaroxaban versus warfarin in obese, AAs with …